

## Diaceutics Full Year 2025 Trading Update

### Reported revenues expected to be £38.5 million, representing 20% growth and a return to profitability

*Revenue on a constant currency basis expected to show 24% growth in line with analyst consensus estimates\**

*FY 2025 Adjusted EBITDA\*\* expected to exceed analyst consensus estimates*

*Record order book of at least £36.8 million*

*ARR of at least £20.3 million*

*12% growth in number of customer therapeutic brands to 95*

*Second PMx commercialisation partnership signed in Q4 with an innovative US Biotech underpinning another year of strong commercial growth*

*Additional top 10 global pharma customer confirmed as an enterprise-wide engagement customer; continue to consistently work with 18 of top 20 global pharma companies*

*The Company expects to deliver 25% revenue growth in FY 2026*

**New York, Belfast and London, 15 January 2026 - [Diaceutics PLC](#)** (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, today provides a trading update for the year ended 31 December 2025 ('FY 2025'), highlighting strong revenue growth, improved profitability and a record order book.

**Ryan Keeling, Diaceutics' Chief Executive Officer, commented:** "2025 marked a step-change year for Diaceutics as we executed an ambitious value-creation programme focused on scale, profitability and recurring revenues. Through disciplined go-to-market execution and the comprehensive deployment of AI across the business, we have accelerated our transition to a high-quality ARR model with improving margins. We delivered another year of robust commercial performance, underpinned by expanding adoption across therapeutic brands and deeper enterprise-wide customer engagements. Importantly, this growth was achieved against a more challenging industry backdrop, demonstrating both the mission-critical nature of our offering and the resilience of our revenue model. Our continued investment in agentic AI is now driving tangible operating leverage, enhancing customer outcomes while improving internal efficiency and scalability. As a result, we enter 2026 with a record order book and a strong forward sales pipeline, providing clear visibility on future growth. With strong commercial momentum, a scalable platform and a proven execution engine, we are confident in delivering another year of high-quality growth and continued value creation in 2026."

### Trading Update to 31 December 2025

Reported revenues are expected to be £38.5 million (FY 2024: £32.2 million), representing growth of 20% in the year and equating to a 3-year Compound Annual Growth Rate ('CAGR') of 25%. On a constant currency basis, underlying revenue would equate to £40.0 million delivering a growth rate of 24%, which is in line with analyst consensus estimates\*.

The Company returned to profitability (Profit After Tax) in FY 2025, and Adjusted EBITDA\*\* is expected to be above analyst consensus estimates\* representing growth of approximately 75% year-on-year ('YoY') and an Adjusted EBITDA\*\* margin of approximately 19%.

The visibility and sustainability of revenues continued to improve during the year. Annual Recurring Revenue ('ARR') increased 21% and is expected to be in excess of £20.3 million ( £20.4 million) as at 31 December 2025 (£16.8 million ( £16.1 million) at 31 December 2024), representing USD YoY ARR growth in excess of 30%. The multi-year nature of the order book continued to expand and is expected to be in excess of £36.8 million as at 31 December 2025 (£24.9 million at 31 December 2024), a YoY growth of 48%.

Diaceutics added three new enterprise-wide customers in FY 2025, including its second multi-year PMx commercialisation partnership with a leading US biotech. PMx integrates real-time multi-modal data lab

commercialisation partnership with a leading US biotech. DXRX integrates real-time multi-modal data, lab networks, digital outreach and peer-to-peer education to drive precision therapy adoption. Ten enterprise-wide engagements are now live across 36 brands, generating £13.0 million in ARR (£10.6 million in FY 2024). Enterprise-wide engagements are defined as customers deploying the DXRX platform across three or more of the brands in their portfolio, or where Diaceutics is the primary commercialisation partner for their precision medicine.

Diaceutics continues to work with 18 of the top 20 global pharma companies, and supported a total of 53 customers across 95 therapeutic brands in FY 2025 (FY 2024: 52 customers and 85 therapeutic brands).

#### Outlook

- Global pharma and biotech customers are continuing to accelerate their shift to precision medicine to improve patient access, capture lost revenue and optimise commercial outcomes
- Ongoing enhancements to the DXRX platform are delivering operational leverage
- Started to secure opportunities beyond precision medicine, supporting new therapeutic brands and expanded revenue opportunities
- The Company expects to deliver 25% revenue growth in FY 2026

*All numbers stated are approximate and subject to audit.*

*\* Analyst consensus estimates for FY 2025 revenue is £39.5 million and Adjusted EBITDA is £7.1 million.*

*\*\* Adjusted EBITDA is earnings before interest, tax, depreciation, amortisation and exceptional items.*

#### Enquiries:

##### Diaceutics PLC

Ryan Keeling, Chief Executive Officer

Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500

[investorrelations@diaceutics.com](mailto:investorrelations@diaceutics.com)

##### Canaccord Genuity Limited (Nomad & Broker)

Simon Bridges, Andrew Potts, Harry Rees

Tel: +44 (0)20 7523 8000

#### About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

Prior to publication the information communicated in this announcement was deemed by the Company to constitute inside information for the purposes of article 7 of the Market Abuse Regulations (EU) No 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations No 2019/310 ('MAR'). With the publication of this announcement, this information is now considered to be in the public domain. The person responsible for making this announcement on behalf of the Company is Nick Roberts, Chief Financial Officer.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TSTFFFFFLRISLIR